Literature DB >> 20472443

Controlled release of PEG chain from gold nanorods: targeted delivery to tumor.

Takuro Niidome1, Akira Ohga, Yasuyuki Akiyama, Kazuto Watanabe, Yasuro Niidome, Takeshi Mori, Yoshiki Katayama.   

Abstract

Gold nanorods exhibit strong absorbance of light in the near infrared region, which penetrates deeply into tissues. Since the absorbed light energy is converted into heat, gold nanorods are expected to act as a contrast agent for in vivo bioimaging and as a thermal converter for photothermal therapy. To construct a gold nanorod targeted delivery system for tumor a peptide substrate for urokinase-type plasminogen activator (uPA), expressed specifically on malignant tumors, was inserted between the PEG chain and the surface of the gold nanorods. In other words, we constructed PEG-peptide-modified gold nanorods. After mixing the gold nanorods with uPA, the PEG chain was released from the surface of the gold and subsequently nanorod aggregation took place. The formation of the aggregation was monitored as a decrease in light absorption at 900 nm. Tumor homogenate induced a significant decrease in this absorption. Larger amount of the PEG-peptide-modified gold nanorods bound to cells expressing uPA in vitro compared with control gold nanorods, which had scrambled sequence of the peptide. The PEG-peptide-modified gold nanorods showed higher accumulation in tumor than the control after they were injected intravenously into tumor-bearing mice, however, the density of the peptide on the surface of the gold nanorods was a key factor of their biodistributions. This targeted delivery system, which responds to uPA activity, is expected to be a powerful tool for tumor bioimaging and photothermal tumor therapy. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472443     DOI: 10.1016/j.bmc.2010.04.070

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

Review 1.  Extracellularly activatable nanocarriers for drug delivery to tumors.

Authors:  Sara A Abouelmagd; Hyesun Hyun; Yoon Yeo
Journal:  Expert Opin Drug Deliv       Date:  2014-06-20       Impact factor: 6.648

Review 2.  Recent advances in stealth coating of nanoparticle drug delivery systems.

Authors:  Zohreh Amoozgar; Yoon Yeo
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-01-09

3.  Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles.

Authors:  Emily Gullotti; Joonyoung Park; Yoon Yeo
Journal:  Pharm Res       Date:  2013-04-23       Impact factor: 4.200

4.  Biocompatible Gold Nanorod Conjugates for Preclinical Biomedical Research.

Authors:  Anton Liopo; André Conjusteau; Dmitri Tsyboulski; Boris Ermolinsky; Alexander Kazansky; Alexander Oraevsky
Journal:  J Nanomed Nanotechnol       Date:  2012-08-03

5.  Improved Delivery Performance of n-Butylidenephthalide-Polyethylene Glycol-Gold Nanoparticles Efficient for Enhanced Anti-Cancer Activity in Brain Tumor.

Authors:  Ming-Tai Hsing; Hui-Ting Hsu; Chih-Hsuan Chang; Kai-Bo Chang; Chun-Yuan Cheng; Jae-Hwan Lee; Chien-Li Huang; Meng-Yin Yang; Yi-Chin Yang; Szu-Yuan Liu; Chun-Ming Yen; Shun-Fa Yang; Huey-Shan Hung
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

Review 6.  Recent Progress in Bio-Responsive Drug Delivery Systems for Tumor Therapy.

Authors:  Xiufeng Cong; Jun Chen; Ran Xu
Journal:  Front Bioeng Biotechnol       Date:  2022-06-29

7.  Tissue distribution and efficacy of gold nanorods coupled with laser induced photoplasmonic therapy in ehrlich carcinoma solid tumor model.

Authors:  Mostafa A El-Sayed; Ali A Shabaka; Osama A El-Shabrawy; Nemat A Yassin; Sawsan S Mahmoud; Siham M El-Shenawy; Emad Al-Ashqar; Wael H Eisa; Niveen M Farag; Marwa A El-Shaer; Nabila Salah; Ahmed M Al-Abd
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

Review 8.  Gold Nanorods for Drug and Gene Delivery: An Overview of Recent Advancements.

Authors:  Atieh Jahangiri-Manesh; Marziyeh Mousazadeh; Shirinsadat Taji; Abbas Bahmani; Atefeh Zarepour; Ali Zarrabi; Esmaeel Sharifi; Mostafa Azimzadeh
Journal:  Pharmaceutics       Date:  2022-03-17       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.